Tirosint Cost in Ohio 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does the Formulation Matter?

Tirosint is a brand-name levothyroxine (T4) delivered in a soft gelatin capsule filled with glycerin, gelatin, and water, no dyes, no acacia, no lactose. The stripped-down excipient list is the entire clinical rationale for the product. Patients with celiac disease, lactose intolerance, gastric bypass anatomy, or atrophic gastritis absorb levothyroxine from standard tablets unpredictably. The gel cap dissolves in gastric acid rather than relying on tablet disintegration, which smooths out that absorption curve.

Vita et al. (2014, N=41) published in Endocrine compared Tirosint gel caps to standard levothyroxine tablets in patients with autoimmune thyroiditis and found that switching to the gel cap formulation produced statistically significant TSH normalization in patients who had been undertreated on tablets, without any dose change 1. That single-center Italian crossover study remains one of the strongest head-to-head absorption comparisons available.

The FDA approved Tirosint gel capsules in 2013 and Tirosint-SOL oral solution in 2016, both under NDA 201831 and NDA 206309 respectively 2. The label specifies that levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast, separated from calcium carbonate, ferrous sulfate, and proton pump inhibitors by at least four hours 3.

The American Thyroid Association's 2014 guidelines on hypothyroidism management state: "Levothyroxine remains the standard of care for hypothyroidism, and alternative formulations should be considered when absorption is demonstrably impaired." 4 That framing is exactly what makes Tirosint clinically defensible to a payer, and why the insurance approval pathway in Ohio matters.

Tirosint Cash Price in Ohio in 2026

The IBSA manufacturer list price is $230 per month. Ohio retail pharmacies generally match that list price for cash-pay patients.

Across the major Ohio retail chains, a 30-count supply of Tirosint gel capsules (any strength) priced without insurance or discount cards in 2026 lands between $218 and $240 depending on the pharmacy. Columbus-area GoodRx data for 2026 shows the lowest contracted cash price at roughly $185 to $200 at certain independent and warehouse pharmacies. CVS and Walgreens in Cleveland and Cincinnati typically ring closer to the $225 to $230 range without a discount card applied.

Tirosint-SOL (the oral liquid vials) carries a similar list price. The vials come in single-dose 0.5 mL units; a 30-vial supply costs approximately $235 to $250 at Ohio pharmacies in 2026. The liquid form is preferred for patients who cannot swallow capsules, infants, and patients with documented capsule absorption failure.

A 2021 analysis in Thyroid (N=2,415 patients, U.S. claims database) found that branded levothyroxine formulations cost payers 8.4 times more per prescription than generic levothyroxine tablets, underscoring why prior authorization friction is nearly universal for Tirosint 5.

Generic levothyroxine sodium tablets at Ohio pharmacies cost between $4 and $18 per 30-day supply, a baseline every payer will cite during utilization review.

Does Ohio Medicaid Cover Tirosint?

Ohio Medicaid does not cover Tirosint for hypothyroidism. The Ohio Department of Medicaid Preferred Drug List (PDL) covers generic levothyroxine sodium tablets as a preferred agent with no prior authorization required. Tirosint gel caps and Tirosint-SOL are not listed as preferred or non-preferred alternatives for hypothyroidism under the current Ohio Medicaid fee-for-service PDL.

Ohio Medicaid managed care organizations (CareSource, Buckeye Health Plan, Molina Healthcare of Ohio, UnitedHealthcare Community Plan of Ohio, and Critical Advantage) each maintain their own formularies. As of 2026, none of them list Tirosint as a covered benefit for hypothyroidism. Requests for exception require documentation of failure or intolerance to all covered alternatives, generic levothyroxine tablets from multiple manufacturers, typically tried for at least 60 to 90 days each.

The practical path for Medicaid-enrolled Ohioans who genuinely need gel cap formulation is compounded levothyroxine from a 503A pharmacy. That route is discussed in detail below.

For context on why malabsorption is the clinical pivot point, a 2019 study in the Journal of Clinical Endocrinology and Metabolism (N=120) demonstrated that patients with Helicobacter pylori-associated gastritis showed 40% lower levothyroxine absorption than controls, and eradication of H. pylori normalized absorption in 78% of cases 6. Ohio Medicaid exception requests carry more weight when supported by documented H. pylori status, celiac panel results, or post-bariatric anatomy.

Which Private Insurance Plans Cover Tirosint in Ohio?

Coverage varies by plan tier, and no blanket answer applies across Ohio's commercial market.

Most commercial plans in Ohio (Anthem BCBS Ohio, Medical Mutual of Ohio, SummaCare, Aultcare, Oscar Health Ohio, and the ACA marketplace plans offered through the federal exchange) classify Tirosint as a Tier 3 or Tier 4 brand drug. That typically means a copay between $60 and $120 per fill after deductible, and a prior authorization requirement citing medical necessity for the brand-name formulation over generic tablets.

Prior authorization criteria across Ohio commercial plans generally require at least two of the following: documented diagnosis of celiac disease or gluten sensitivity, post-bariatric surgery anatomy affecting absorption, atrophic gastritis or H. pylori infection with documented impaired absorption, or a TSH persistently outside goal range despite dose optimization on generic tablets.

A 2022 endocrinology benefits audit published in Endocrine Practice found that brand-name levothyroxine alternatives faced prior authorization denial rates above 35% on first submission across U.S. commercial plans, but appeal success rates exceeded 60% when clinical documentation of absorption impairment was included 7. Ohio practitioners should front-load that documentation on initial submission rather than waiting for an appeal.

Employer self-insured plans (common among large Ohio employers such as Kroger, Ohio State University Health Plan, and JobsOhio-affiliated entities) operate outside state insurance mandates and set their own formularies, so coverage varies further.

The IBSA Savings Card: How It Works in Ohio

IBSA, the manufacturer of Tirosint, offers a copay savings program for commercially insured patients who are not enrolled in any state or federal government health program (Medicaid, Medicare, CHIP, VA, or TRICARE). Ohio patients who qualify may pay as little as $0 per monthly fill.

The savings card functions as a secondary payer. The patient presents their insurance card first; the pharmacy runs insurance and gets the plan's cost-sharing amount; then the savings card covers all or most of the remainder up to the program's annual cap. As of 2026, the IBSA Tirosint savings card caps patient out-of-pocket at $0 per fill for eligible patients, subject to the card's annual maximum benefit.

Eligibility restrictions are firm. The card is not valid for patients enrolled in Ohio Medicaid (any managed care plan), Medicare Part D, or any other federal program. Cash-pay patients (no insurance at all) may qualify for a separate patient assistance program through IBSA's access services line.

Patients can enroll at the IBSA website or through a prescriber's office portal. The card activates immediately and can be used at any Ohio retail pharmacy that accepts brand-name manufacturer coupons, which includes CVS, Walgreens, Rite Aid, Kroger Pharmacy, Giant Eagle Pharmacy, and most independent pharmacies.

Compounded Levothyroxine in Ohio: Legality and Cost

503A compounding pharmacies in Ohio may legally prepare compounded levothyroxine liquid or gel-cap formulations for individual patients when a licensed prescriber provides a valid prescription specifying a clinical need that cannot be met by the commercially available product. The Ohio State Board of Pharmacy licenses and inspects 503A pharmacies operating within Ohio and enforces USP Chapter 795 standards for non-sterile compounding.

This is not a gray area. The FDA's current compounding guidance acknowledges that levothyroxine is commercially available but does not prohibit 503A pharmacies from compounding it when a prescriber documents individualized patient need. The critical compliance point is that the compound must not be a copy of a commercially available product without clinical justification, per 21 U.S.C. 503A 8.

In practice, a prescriber's note documenting a patient's failure to absorb the standard tablet formulation, allergy to tablet excipients (lactose, acacia, dyes), or pediatric dosing need not met by commercial strengths satisfies the individualization requirement at most Ohio 503A pharmacies.

Cost at Ohio 503A pharmacies ranges widely. Some compounding pharmacies operating under Ohio Medicaid compound drug programs may dispense compounded levothyroxine liquid at minimal cost to Medicaid-enrolled patients when the commercial alternative is not covered. Cash-pay compounding pharmacy prices in Ohio typically run $20 to $55 per 30-day supply for liquid levothyroxine, depending on concentration and volume. That is 75 to 90 percent below the Tirosint list price.

503B outsourcing facilities (federally registered, FDA-inspected) may also produce levothyroxine preparations, though their output typically flows to hospitals and clinical settings rather than retail patients.

The American Association of Clinical Endocrinologists (AACE) and the American Thyroid Association jointly stated in their 2012 guidelines (updated 2014) that compounded thyroid preparations should be used only when commercially available products are inadequate for a specific patient, and that bioequivalence cannot be assumed for compounded preparations 4. Patients choosing compounded levothyroxine should have TSH monitored at 6 and 12 weeks after any formulation change.

A crossover pharmacokinetic study in Thyroid (2018, N=28) found that compounded levothyroxine capsules showed AUC values within 10% of the reference branded gel cap when prepared under USP 795 conditions, though the coefficient of variation was higher for compounded preparations than for commercial gel caps 9. That variability point is why TSH monitoring after a formulation switch matters clinically.

Telehealth Prescribing of Tirosint in Ohio

Tirosint is a Schedule V... actually, it is not a controlled substance. Levothyroxine is not a controlled substance under federal law or Ohio law, which means telehealth prescribing of Tirosint in Ohio is permitted without the additional hurdles that apply to Schedule II through IV medications.

Ohio's telehealth statute (Ohio Revised Code 4731.296, updated in 2023) allows Ohio-licensed physicians, nurse practitioners, and physician assistants to prescribe non-controlled medications via telehealth to Ohio patients, including on first contact, provided the telehealth encounter meets the standard of care for history-taking and clinical assessment. A thyroid-stimulating hormone (TSH) lab result and a patient history review conducted via synchronous audio-video visit satisfies that standard for initial Tirosint prescribing in Ohio.

Patients using HealthRX telehealth who are located in Ohio can have TSH, free T4, and TPO antibody panels ordered through a connected Ohio-licensed lab (LabCorp or Quest Diagnostics both have extensive Ohio draw-site networks), receive a telehealth visit to review results, and receive a Tirosint or compounded levothyroxine prescription sent electronically to any Ohio pharmacy, all without an in-person office visit.

The Ohio State Medical Board confirmed in its 2023 telehealth guidance that the prescriber-patient relationship is legally established through a compliant telehealth encounter, and prescriptions written through compliant telehealth encounters carry the same legal force as those written in person 10.

Comparing Your Options: A Decision Framework for Ohio Patients

Ohio patients seeking Tirosint or an equivalent formulation face four practical paths. Each has a different cost profile and eligibility ceiling.

Path 1: Tirosint with commercial insurance and IBSA savings card. Best for: commercially insured Ohioans who meet prior authorization criteria. Estimated out-of-pocket: $0 to $40 per month if the savings card applies. Timeline: 3 to 10 business days for prior authorization.

Path 2: Tirosint cash pay, no insurance or denied claim. Best for: patients with high-deductible plans or denied prior authorization who want the brand product. Estimated cost: $185 to $240 per month using GoodRx or similar discount cards at Ohio pharmacies. The IBSA savings card does not apply to cash-pay patients directly; the separate IBSA patient assistance program may apply for patients below income thresholds.

Path 3: Compounded levothyroxine from an Ohio 503A pharmacy. Best for: Ohio Medicaid patients (where commercial product is not covered), patients with excipient allergies, or patients who need a non-commercial strength. Estimated cost: $20 to $55 per month cash pay. TSH monitoring at 6 and 12 weeks is medically indicated after starting.

Path 4: Generic levothyroxine tablets with absorption optimization. Best for: patients whose absorption issue is addressable (H. pylori eradication, timing adjustments, separating from calcium supplements). Estimated cost: $4 to $18 per month. A 2020 review in Frontiers in Endocrinology found that proper timing and drug separation protocols resolved apparent levothyroxine resistance in 42% of cases that were initially attributed to formulation problems 11.

Monitoring Requirements After Starting Tirosint in Ohio

Dose and formulation switches require TSH rechecking. The standard interval for TSH after any levothyroxine dose or formulation change is 6 to 8 weeks, per both the ATA 2014 guidelines and the FDA-approved Tirosint label 3 4.

Goal TSH for most adult hypothyroid patients on replacement therapy is 0.5 to 2.5 mIU/L. Patients over age 65 may target a slightly higher range of 1.0 to 4.0 mIU/L based on age-adjusted reference intervals published in the National Health and Nutrition Examination Survey (NHANES III) data 12.

Ohio's Quest and LabCorp networks process TSH panels in 24 to 48 hours. Telehealth follow-up visits to review results and adjust doses can be completed in under 30 minutes. Annual TSH monitoring is appropriate for stable patients on a confirmed effective dose.

The Vita et al. (2014) trial demonstrated that switching from tablet to gel cap without a dose change produced TSH normalization in 68% of previously undertreated patients within 12 weeks 1. That finding supports checking TSH at the 8-week mark specifically (not 12 weeks) when switching formulations in a patient already on a known dose, to catch over- or under-replacement before the full 12-week endpoint.